InterCure Ltd
TASE:INCR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
444
1 254
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
InterCure Ltd
Cost of Revenue
InterCure Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
InterCure Ltd
TASE:INCR
|
Cost of Revenue
-₪247.2m
|
CAGR 3-Years
-93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-63%
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Cost of Revenue
-$8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Cost of Revenue
-$17.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-35%
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Cost of Revenue
-₪119.9m
|
CAGR 3-Years
-79%
|
CAGR 5-Years
-81%
|
CAGR 10-Years
-58%
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Cost of Revenue
-₪248.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-3%
|
|
InterCure Ltd
Glance View
InterCure Ltd. engages in the business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
See Also
What is InterCure Ltd's Cost of Revenue?
Cost of Revenue
-247.2m
ILS
Based on the financial report for Dec 31, 2023, InterCure Ltd's Cost of Revenue amounts to -247.2m ILS.
What is InterCure Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-63%
Over the last year, the Cost of Revenue growth was -8%. The average annual Cost of Revenue growth rates for InterCure Ltd have been -93% over the past three years , and -63% over the past ten years .
You don't have any saved screeners yet
